Yahoo · Sep 9, 2026
Why Is Hims & Hers Health (HIMS) Down 7.7% Since Last Earnings Report?
Hims & Hers Health (HIMS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
HI
NYSE · HIMS
Hims & Hers Health, Inc.
Healthcare · Medical - Equipment & Services
$27.85
Down-$0.96 (-3.33%)
Updated Sep 16, 2026, 12:29 PM
SID Score
4.0/10
Composite research score
Smart Money
62/100
Neutral
- Market cap
- 8.28B
- P/E ratio
- 63.9
- Dividend yield
- 0.00%
- 52-week range
- $13.74 – $65.30
- Volume
- 8.16M
- Avg. volume
- 27.1M
Price performance
HIMS price history
1M range · 20 trading sessions · Daily adjusted prices
HIMS closed at $27.85 after 20 trading sessions, up 1.68% for the selected period.
- Last close
- $27.85
- Period change
- +1.68%
- Period low
- $27.39
- Period high
- $33.78
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $28.30 | $29.16 | $27.80 | $27.85 | 8.16M |
| Sep 14, 2026 | $27.38 | $29.44 | $27.14 | $28.81 | 11.98M |
| Sep 11, 2026 | $27.41 | $27.63 | $26.73 | $27.51 | 7.09M |
| Sep 10, 2026 | $27.30 | $28.00 | $27.1205 | $27.44 | 7.57M |
| Sep 9, 2026 | $28.10 | $28.28 | $27.27 | $27.90 | 8.44M |
| Sep 8, 2026 | $27.73 | $28.33 | $27.61 | $28.17 | 8.57M |
| Sep 4, 2026 | $27.73 | $27.95 | $27.38 | $27.71 | 7.18M |
| Sep 3, 2026 | $28.88 | $29.12 | $27.55 | $27.82 | 12.21M |
| Sep 2, 2026 | $28.33 | $29.375 | $28.15 | $28.68 | 7.9M |
| Sep 1, 2026 | $29.28 | $29.87 | $28.38 | $28.44 | 7.3M |
| Aug 31, 2026 | $28.67 | $29.7898 | $28.63 | $29.58 | 8.31M |
| Aug 28, 2026 | $31.36 | $31.40 | $28.52 | $28.84 | 14.73M |
| Aug 27, 2026 | $30.40 | $31.985 | $29.7244 | $31.66 | 9.62M |
| Aug 26, 2026 | $31.04 | $31.6295 | $29.62 | $29.83 | 11.58M |
| Aug 25, 2026 | $31.29 | $32.51 | $30.73 | $31.75 | 9.64M |
| Aug 24, 2026 | $32.44 | $32.72 | $30.30 | $31.08 | 13.87M |
| Aug 21, 2026 | $31.67 | $34.4556 | $31.60 | $33.78 | 14.71M |
| Aug 20, 2026 | $30.66 | $33.16 | $30.66 | $31.86 | 18.93M |
| Aug 19, 2026 | $27.55 | $31.27 | $27.41 | $31.09 | 20.01M |
| Aug 18, 2026 | $27.85 | $28.85 | $27.38 | $27.39 | 7.93M |
Latest HIMS news
The latest Smart Investors Daily articles mentioning HIMS.
Stock researchCompany · Overview
HIMS research
Overview
Company profile and research snapshot.
Company profile
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $42.83
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 24, 2026 | Truist Securities | Hold | — |
| Aug 21, 2026 | Barclays | Overweight | — |
| Aug 11, 2026 | Morgan Stanley | Equal-Weight | — |
| Aug 11, 2026 | TD Cowen | Hold | — |
| Aug 11, 2026 | B of A Securities | Neutral | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 8, 2026
Hims & Hers Health, Inc. (HIMS) Gains As Market Dips: What You Should Know
The latest trading day saw Hims & Hers Health, Inc. (HIMS) settling at $28.17, representing a +1.66% change from its previous close.
Yahoo · Sep 8, 2026
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
Yahoo · Sep 7, 2026
Here's Why Teladoc's Integrated Care Business Deserves More Attention
TDOC's Integrated Care is driving profitability as chronic care gains traction, potentially making it the company's key earnings driver.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
